



# Median Technologies

## Corporate Update

**Fredrik Brag, CEO and Founder**

*Webcast – July 12, 2022*



European Rising Tech  
LABEL

[www.mediantechologies.com](http://www.mediantechologies.com)



- The information provided in this presentation pertaining to Median Technologies SA ("Median" or the "Company"), its business assets, strategy and operations is for general informational purposes only and is not a formal offer to sell or a solicitation of an offer to buy any securities, options, futures, or other derivatives related to securities in any jurisdiction and its content is not prescribed by securities laws. Information contained in this presentation should not be relied upon as advice to buy or sell or hold such securities or as an offer to sell such securities. This presentation does not take into account nor does it provide any tax, legal or investment advice or opinion regarding the specific investment objectives or financial situation of any person. While the information in this presentation is believed to be accurate and reliable, Median and its agents, advisors, directors, officers, employees and shareholders make no representation or warranties, expressed or implied, as to the accuracy of such information and Median expressly disclaims any and all liability that may be based on such information or errors or omissions thereof. Median reserves the right to amend or replace the information contained herein, in part or entirely, at any time, and undertakes no obligation to provide the recipient with access to the amended information or to notify the recipient thereof.
- Neither Median nor any of Median's representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this presentation by you or any of your representatives or for omissions from the information in this presentation. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed in this presentation.
- This presentation is intended only for persons who (i) have professional experience in matters relating to investments within the meaning of "investment professionals" as defined, (ii) to whom an invitation or inducement to engage in investment activity in connection with the issuance or sale of securities may be lawfully communicated to or caused to be communicated to (all such persons together being referred to as "Qualified Persons"). This presentation is intended for Qualified Persons only and cannot be given to persons who are not Qualified Persons. Any investment or investment activity to which this presentation refers is permitted for Qualified Persons only and will be denied to any other person.
- Certain information in this presentation and oral statements made in any meeting are forward-looking and relate to Median and its anticipated financial position, business strategy, events and courses of action. Words or phrases such as "anticipate," "objective," "may," "will," "might," "should," "could," "can," "intend," "expect," "believe," "estimate," "predict," "potential," "plan," "is designed to" or similar expressions suggest future outcomes. Forward-looking statements and financial projections include, among other things, statements about: our expectations regarding our expenses, sales and operations; our future customer concentration; our anticipated cash needs, our estimates regarding our capital requirements, our need for additional financing; our ability to anticipate the future needs of our customers; our plans for future products and enhancements of existing product or services; our future growth strategy and growth rate; our future intellectual property; and our anticipated trends and challenges in the markets in which we operate. Forward-looking statements and financial projections are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements and financial projections. Although we believe that the expectations reflected in the forward-looking statements and financial projections are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, level of activity, performance or achievements and there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking statements and financial projections.
- By their nature, forward-looking statements and financial projections involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking information will not occur, which may cause the Company's actual performance and financial results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements and financial projections. Important factors that could cause actual results to differ materially from expectations include, but are not limited to: business, economic and capital market conditions; the heavily regulated industry in which the Company carries on business; current or future laws or regulations and new interpretations of existing laws or regulations; legal and regulatory requirements; market conditions and the demand and pricing for our products; our relationships with our customers, developers and business partners; our ability to successfully define, design and release new products in a timely manner that meet our customers' needs; our ability to attract, retain and motivate qualified personnel; competition in our industry; competition; technology failures; failure of counterparties to perform their contractual obligations; systems, networks, telecommunications or service disruptions or failures or cyber-attack; ability to obtain additional financing on reasonable terms or at all; our ability to manage risks inherent in foreign operations; litigation costs and outcomes; our ability to successfully maintain and enforce our intellectual property rights and defend third party claims of infringement of their intellectual property rights; our ability to manage foreign exchange risk and working capital; and our ability to manage our growth. Readers are cautioned that this list of factors should not be construed as exhaustive.
- The forward-looking statements and financial projections contained in this presentation are expressly qualified by this cautionary statement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Readers are cautioned not to place undue reliance on forward-looking statements or financial projections. Prospective investors should not construe the contents of this presentation as legal, tax, investment or other advice. All prospective investors should make their own inquiries and consult their own advisors as to legal, tax, investment, and related matters concerning an investment in the securities of the Company.

# Strong Business Momentum

*As of June 30, 2022*

## H1 2022 revenue at €12.7M

- Record high revenue of €7M in Q2 2022, up 43% compared with Q2 2021


## Order backlog at €60M

- +15% relative to June 30, 2021
- Activity back to normal after temporary impact of the lockdown in Shanghai


## Cash and cash equivalents at €28.2M

- Cash temporarily affected by the lockdown in Shanghai
- Estimated delayed cash collection of €2.5M

Quarterly revenue evolution (m€)



Order backlog evolution (m€)




# iBiopsy<sup>®</sup>: Setting the Bar in Lung Cancer Screening



*Unrivalled accuracy in automatic lung nodule detection & characterization on all lung cancer stages*

- **Automatic Lung Nodule detection and Characterization**
  - Cohort: 1,760 NLST patients (16,789 Nodules)
  - Test set:
    - › 4,681 nodules (151 malignant, 4,531 benign)
    - › 471 patients (146 malignant, 325 benign)
- **Model: Combination of Deep Neural Networks, 3D-Morphological and Radiomics features**
- **Lesion Level Performance**
  - **AUC = 0.976**
  - Max Youden index
    - Sensitivity = 94.7 %**
    - Specificity = 93.3 %**



# AI-Powered Imaging and Data-Driven Approach Are Redefining the Entire Patient Journey

## Oncology Clinical Trials

## Translational Research in Oncology

## Patient Care: Early Diagnosis & Disease Monitoring



Imaging Lab services


Bringing more data  
insights to  
biopharmaceutical  
companies



AI & Data mining technologies

- Stage shift of biopharmaceutical companies towards early-stage cancers
- Better understanding of drugs mechanisms of action

# iBiopsy<sup>®</sup> Product Roadmap





## Our Core Values

### **Leading innovation with purpose**

Combine the spirit of innovation with our passion and conviction to help cure cancer and other debilitating diseases.

### **Committing to quality in all we do**

Be dedicated to quality in everything we do. Quality begins with us and we are committed to it.

### **Supporting our customers in achieving their goals**

Listen to the needs of our customers and help make their goals our goals through our innovation, imaging expertise, superior services, and quality solutions.

### **Putting the patient first**

There is a person at the other end of the images we analyze who is counting on us to do everything we can to help make them healthier.



European **Rising Tech**  
LABEL

[www.mediantechologies.com](http://www.mediantechologies.com)